Asthma

GSK to Buy Respiratory Drug Developer Aiolos Bio

GSK has agreed to acquire biotech Aiolos Bio for a $1 billion upfront payment and up to $400 million for the achievement of certain milestones. Founded just last year, Aiolos is a San Francisco, USA and London, UK-based biopharmaceutical company that develops treatments for respiratory diseases.

Topics • Technology

Bioelectronic Medicines: A New Type of Personalization

Top-Feature

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Aenova Holding GmbH

Mastering Modified Release: The Pellet-Based Approach

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Interview

Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Chemical Market Reporter